TABLE 2

Demographic Characteristics

Continuers (n = 16)Discontinuers (n = 20)
Age, years58.3 ± 8.558.3 ± 8.9
Sex
 Male5 (31.2)5 (20.0)
 Female11 (68.8)16 (80.0)
Highest level of education completed
 Some high school1 (6.3)2 (10.0)
 High school graduate5 (31.3)6 (30.0)
 Some college7 (43.7)11 (55.0)
 Bachelor’s degree3 (18.7)1 (5.0)
Current employment outside the home
 Employed part-time or full-time11 (68.8)5 (25.0)
 Retired2 (12.5)4 (20.0)
 Not employed3 (18.8)11 (55.0)
Annual household income, $
 5,000–14,9992 (12.5)1 (5.0)
 15,000–34,9997 (35)
 35,000–49,9993 (18.8)5 (25.0)
 ≥50,0009 (56.3)7 (35.0)
Racial group
 White or Caucasian13 (81.2)18 (90.0)
 Black or African American2 (12.5)
 Other1 (6.3)1 (5.0)
 Unknown1 (5.0)
A1C at start of GLP-1 receptor agonist, %7.7 ± 0.98.2 ± 1.4
(n = 12)(n = 10)
Most recent A1C, %7.5 ± 1.37.9 ± 1.9
(n = 16)(n = 19)
Diabetes duration, years12.7 ± 7.515.3 ± 8.4
 Duration of current GLP-1 receptor agonist therapy, months
  >613 (81.3)
  <63 (18.8)
Time since discontinuation, months
 >65 (25.0)
 <615 (75.0)
Current GLP-1 receptor agonist therapy
 Once-daily liraglutide5 (31.3)
 Once-weekly exenatide4 (25.0)
 Twice-daily exenatide2 (12.5)
 Once-weekly dulaglutide5 (31.3)
  • Data are mean ± SD or n (%).